CNTB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Connect Biopharma Holdings Ltd (CNTB) is not a good buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of positive trading signals, weak financial performance, and absence of significant catalysts make this stock unsuitable for the user's investment profile.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 45.691, suggesting no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock's recent price drop (-7.84%) and weak support/resistance levels (Pivot: 2.513, S1: 2.295, R1: 2.731) indicate limited upside potential in the near term.
NULL identified. No recent news, no significant hedge fund or insider activity, and no congress trading data available.
The stock has seen a significant price decline (-7.84%) in the last session. Financials for Q3 2025 show a massive revenue drop (-98.69% YoY), and while net income and EPS improved, they remain negative. The stock also has a 40% chance of further declines in the next day (-0.48%), week (-2.7%), and month (-0.7%).
In Q3 2025, revenue dropped significantly to $16,000 (-98.69% YoY). Net income improved to -$17,200,000 (+33.58% YoY), and EPS increased to -0.31 (+34.78% YoY). Gross margin remained flat at 100%. Overall, the financial performance is weak, with no clear growth trends.
No data on analyst ratings or price target changes is available.
